Navigation Links
Nile Therapeutics Reports 2010 Second Quarter Financial Results
Date:8/16/2010

SAN MATEO, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.

Financial ResultsFor the three months ended June 30, 2010, Nile reported a net loss of approximately $1.5 million, or $0.05 per share, compared to a net loss of approximately $2.5 million, or $0.10 per share, during the second quarter of 2009. Weighted-average shares outstanding for the second quarter were 32.3 million.

Net cash used in operating activities in the second quarter of 2010 was approximately $1.0 million; net cash provided by financing activities was approximately $4.5 million; and net cash increase in the second quarter of 2010 was approximately $3.6 million. As of June 30, 2010, Nile had cash and cash equivalents of approximately $5.6 million compared to approximately $3.2 million as of December 31, 2009.

Update on CD-NPDuring June 2010, Nile completed enrolling a placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure ("ADHF") in the United States, Germany and Israel. In total, 77 patients were randomized into four doses of CD-NP (1.25, 2.5, 3.75 and 5 ng/kg/min) vs. placebo. The last patient visit occurred at the end of July and final results from the study are expected in the fourth quarter of 2010. Also in the fourth quarter of 2010, Nile plans to submit to the FDA for review and discussion, the clinical protocol for a double-blind, placebo controlled Phase IIb study of CD-NP in ADHF patients.

About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developin
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors ... Ph.D., Chief Scientific Officer, will present at the Stem ... on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... , Sept. 30, 2014  According to ... world of cancer clinical trials is going through ... trials and the work of the current clinical ... types of ,next generation, clinical trials, which will ... The company has been recognized ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
(Date:10/1/2014)... 2014 NoteSwift Inc., announced today their ... 12.1 and 13.0. NoteSwift is the bridge between the ... navigate and document clinical information at the point of ... a patient note by more than half – and ... pain points providers state impedes EHR use according to ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected ... Stewart American Made Awards (MSAMAs), an annual competition in ... the fields of crafts, design, food and style. ... in the MSAMAs, which celebrates entrepreneurs and artisans who ... communities and changing the way we shop, work and ...
(Date:10/1/2014)... Deland, Florida (PRWEB) October 01, 2014 ... to promote awareness and early detection plans while raising ... to support Breast Cancer Awareness Month in ... Water also wants to promote the importance of having ... contaminated drinking water may be linked to certain forms ...
(Date:10/1/2014)... 2014 Today marks the final day ... Institute in Oxnard and Woodland Hills, Calif., is in ... rehabilitation training. , “Speaking to this group of specialists ... to get the help and care they deserve,” Dr. ... previous dental work, providing cosmetic dentistry, correcting bite issues, ...
(Date:10/1/2014)... After undergoing a trial-and-error process in an ... join, Living Well Assisted Living at Home recently joined ... the home of its headquarters. , Although Living Well’s ... thought of adding one more activity to their busy ... the right chamber to join because membership in the ...
Breaking Medicine News(10 mins):Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5Health News:Living Well Joins San Rafael Chamber of Commerce 2Health News:Living Well Joins San Rafael Chamber of Commerce 3
... encourage health care providers to take into account the number ... tumor cells in colon cancer patients, taken during follow up. ... of reccurence , as this number was shown to ... comeback. ,Lymph node evaluation is important for determining ...
... by addiction specialists and published in Lancet Medical journal, tobacco ... drugs. Prof David Nutt from Bristol University headed this research. ... fifth most dangerous drug followed by ketamine, speed and safety. ... less harmful than tobacco and is recently downgraded to class ...
... in the United States has urged drug companies to print ... treat sleep disorder. FDA has also ordered the companies to ... ,Last week the FDA had underlined the harmful effects of ... incidents of weird behavior like cooking food, eating and even ...
... conducted by Dr. Steriani Elavsky, women passing through their menopause ... they exercised. The improvements in heart and respiratory fitness are ... of life. ,This research was carried out on ... on a random basis. One group was assigned to perform ...
... all private hospitals, built on subsidised government land, must ... indoor and outdoor facilities or face contempt of court ... poor "obligatory" at hospitals built on subsidised land, a ... Malhotra said the hospitals are obliged to provide free ...
... World Health Organisation (WHO) has claimed that the global tuberculosis ... it declared TB a public health emergency in 1993. // ... before the world TB day, says that the percentage ... but has held steady in 2005. ,United Nations ...
Cached Medicine News:Health News:Doctors Warned to Keep Track of Tumorous Lymph Nodes 2Health News:Private Clinics on Public Land Must Treat Poor Free: Court 2Health News:Global Tuberculosis Epidemic Levelling Off - WHO 2
... femoral option and tibial insert which provides a ... degrees of flexion to induce a smooth stable ... of flexion. Femoral component comes in a PS ... constrained tibial insert in conjunction with the femur ...
... True to its leadership role within the ... clinical experience of the industry's leading fixed-bearing ... Knee System, with the clinically proven technology ... leading rotating platform knee. ,The result is ...
... The Femoral component of ... soft tissue and bony destruction ... a high rate of long ... for minimum bone resection and ...
... Knee System is taking total knee replacement to ... of clinical experience. One thing has become clear ... several choices for their patients. Surgeon choice ... factor in long-term patient satisfaction. Biomet responded to ...
Medicine Products: